RT Journal Article
T1 CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer
A1 Fraguas Sánchez, Ana Isabel
A1 Fernández Carballido, Ana María
A1 Simancas-Herbada, R.
A1 Martín Sabroso, Cristina
A1 Torres Suárez, Ana Isabel
AB Cannabidiol (CBD) has emerged as a potential agent for breast cancer management. In this work, the potential use of cannabidiol in solution (CBDsol) and encapsulated in polymeric microparticles when combined with paclitaxel (PTX) and doxorubicin (DOX) in breast cancer treatment has been evaluated for the first time using MCF-7 and MDA-MB-231 cells. CBDsol, previously administered at suboptimal concentrations (cell death < 10%), enhanced the PTX and DOX effect in both breast cancer cells. The co-administration of CBDsol and PTX or DOX showed a synergistic effect. PLGA-502 was selected as the most suitable polymer to develop CBD-loaded microparticles. The developed formulation (CBD-Mps) was effective as monotherapy, showing extended antiproliferative activity for at least 10 days, and when combined with PTX or DOX. In fact, the use of CBD-Mps allows the combination of both, pre and co-administration strategies, with a single administration, also showing a significant increase in PTX and DOX antiproliferative activity. Finally, the anticancer effect of both CBDsol and CBD-Mps as monotherapy or in combination with PTX was also confirmed in ovo, usingMDA-MB-231-derived tumours. This data evidences the promising inclusion of CBD in conventional breast cancer chemotherapy and the use of CBD-Mps for the extended release of this cannabinoid, optimising the effect of the chemotherapeutic agents.
PB Elsevier
SN 0378-5173
YR 2019
FD 2019-12-04
LK https://hdl.handle.net/20.500.14352/91685
UL https://hdl.handle.net/20.500.14352/91685
LA eng
NO Fraguas-Sánchez AI, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez AI. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. International Journal of Pharmaceutics 2020;574:118916. https://doi.org/10.1016/j.ijpharm.2019.118916.
NO Complutense University UCM research group “Formulation and bioavailability of new drug products”
NO Complutense Research Fund
NO Spanish Ministry of Education
DS Docta Complutense
RD 11 abr 2025